{
    "Clinical Trial ID": "NCT02732119",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Cohort A",
        "  Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B",
        "INTERVENTION 2: ",
        "  Cohort B",
        "  Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Adult men and women",
        "  Patient has a confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by local laboratory and has HER2-negative breast cancer",
        "  Patient must have either measurable disease by RECIST 1.1 or bone lesions in absence of measurable disease.",
        "  ECOG Performance Status 0 - 1",
        "  Disease refractory to either, AI, tamoxifen or fulvestrant",
        "  Previously treated on any CDK 4/6 inhibitor.",
        "  Patient has adequate bone marrow and organ function.",
        "Exclusion Criteria:",
        "  Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's best judgment.",
        "  Patient has received more than one line of chemotherapy for advanced disease.",
        "  Previous treatment with mTOR inhibitors, or exemestane for advanced disease.",
        "  Progressed on more than one CDK 4/6 inhibitor",
        "  Patient with CNS involvement unless they are at least 4 weeks from prior therapy completion.",
        "  Clinically significant, uncontrolled heart disease and/or recent cardiac events."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Participants With Dose Limiting Toxicities by Preferred Term in Cycle 1 (28 Days) - in Phase I",
        "  A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a reasonably possible relationship to the study medication(s) and is unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 28 days of treatment (cycle 1) and meets any of the criteria defined in the protocol. National Cancer Institute Common Terminology Criteria for Adverse events (NCI CTCAE) version 4.03 will be used for all grading.",
        "  Time frame: Baseline up to 28 days",
        "Results 1: ",
        "  Arm/Group Title: Cohort A",
        "  Arm/Group Description: Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days. If no DLTs occurred, progressed to Cohort B",
        "  Overall Number of Participants Analyzed: 8",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  Febrile neutropenia Grade 3: 1  12.5%",
        "  Neutropenia Grade 4: 0   0.0%",
        "  Thrombocytopenia Grade 4: 0   0.0%",
        "  Cardiac tamponade Grade 4: 1  12.5%",
        "  Diarrhea Grade 3: 1  12.5%",
        "  Hyperglycemia Grade 4: 0   0.0%",
        "Results 2: ",
        "  Arm/Group Title: Cohort B",
        "  Arm/Group Description: Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally",
        "  Overall Number of Participants Analyzed: 10",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  Febrile neutropenia Grade 3: 1  10.0%",
        "  Neutropenia Grade 4: 1  10.0%",
        "  Thrombocytopenia Grade 4: 1  10.0%",
        "  Cardiac tamponade Grade 4: 0   0.0%",
        "  Diarrhea Grade 3: 0   0.0%",
        "  Hyperglycemia Grade 4: 0   0.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 3/8 (37.50%)",
        "  Anaemia 0/8 (0.00%)",
        "  Febrile neutropenia 1/8 (12.50%)",
        "  Neutropenia 2/8 (25.00%)",
        "  Acute coronary syndrome 0/8 (0.00%)",
        "  Atrial fibrillation 0/8 (0.00%)",
        "  Cardiac failure 0/8 (0.00%)",
        "  Cardiac tamponade 1/8 (12.50%)",
        "  Abdominal pain 1/8 (12.50%)",
        "  Diarrhoea 1/8 (12.50%)",
        "  Intestinal obstruction 0/8 (0.00%)",
        "  Nausea 0/8 (0.00%)",
        "Adverse Events 2:",
        "  Total: 3/10 (30.00%)",
        "  Anaemia 0/10 (0.00%)",
        "  Febrile neutropenia 0/10 (0.00%)",
        "  Neutropenia 0/10 (0.00%)",
        "  Acute coronary syndrome 0/10 (0.00%)",
        "  Atrial fibrillation 0/10 (0.00%)",
        "  Cardiac failure 0/10 (0.00%)",
        "  Cardiac tamponade 0/10 (0.00%)",
        "  Abdominal pain 0/10 (0.00%)",
        "  Diarrhoea 0/10 (0.00%)",
        "  Intestinal obstruction 1/10 (10.00%)",
        "  Nausea 0/10 (0.00%)"
    ]
}